Targeting of antigen presenting cells with immunonanotherapeutics
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
A61K-047/00
출원번호
US-0428381
(2009-04-22)
등록번호
US-8343497
(2013-01-01)
발명자
/ 주소
Shi, Jinjun
Alexis, Frank
Iannacone, Matteo
Moseman, Elliott Ashley
Basto, Pamela
Langer, Robert S.
Farokhzad, Omid C.
von Andrian, Ulrich
Tonti, Elena
출원인 / 주소
The Brigham and Women's Hospital, Inc.
대리인 / 주소
Pabst Patent Group LLP
인용정보
피인용 횟수 :
17인용 특허 :
160
초록▼
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface.
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.
대표청구항▼
1. A composition comprising: (1) synthetic nanocarriers formed of a material selected from the group consisting of lipid-based nanoparticles, polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, peptide or protein-based particles comprising
1. A composition comprising: (1) synthetic nanocarriers formed of a material selected from the group consisting of lipid-based nanoparticles, polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, peptide or protein-based particles comprising an immunofeature surface,wherein the immunofeature surface is formed of a plurality of moieties that provide high avidity and low affinity binding to antigen presenting cell (APC) surfaces as compared to antibody binding; and(2) a pharmaceutically acceptable excipient. 2. The composition of claim 1, wherein the immunofeature surface comprises a plurality of moieties, and wherein the plurality of moieties are present in a density equal to or greater than the density required to obtain at least 10% of the maximal immobilization observed for a monoclonal antibody (MAb) in an antigen presenting cell (APC) binding assay, provided that, in the APC binding assay, the half maximal binding density for the plurality of moieties is at least twice the half maximal binding density for the MAb. 3. The composition of claim 2, wherein the plurality of moieties are present in a density equal to or greater than the density required to obtain at least 20% of the maximal immobilization observed for a MAb in the APC binding assay. 4. The composition of claim 2, wherein the half maximal binding density for the plurality of moieties is at least four times the half maximal binding density for the MAb. 5. The composition of claim 2, wherein the APC binding assay comprises: (a) preparing a series of substrates having coatings of a functional moiety at a series of surface coating densities, wherein the functional moiety is capable of binding to dendritic cell (DC) or subcapsular sinus macrophage surface receptors;(b) exposing the series of substrates to single-cell suspensions of DCs or subcapsular sinus macrophages for a predetermined period of time;(c) removing non-adhered APCs from the series of substrates, and fixing the adhered APCs to the series of substrates;(d) quantifying the number of adhered APCs per unit surface area for each substrate in the series of substrates;(e) plotting the result from (d) against the coating density of the functional moiety;(f) obtaining a value for the maximal immobilization by determining the maximum number of adhered APCs per unit surface area for the series of substrates; and(g) obtaining a value for half maximal binding density by determining the surface coating density that provides 50% of the maximum. 6. The composition of claim 2, wherein the MAb is selected from anti-CD1c(BDCA-1) Clone AD5-8E7 and rat anti-mouse CD169, clone 3D6.112, isotype IgG2a. 7. The composition of claim 1, wherein the immunofeature surface comprises a B-cell antigen. 8. The composition of claim 1, wherein the immunofeature surface comprises a plurality of different moieties. 9. The composition of claim 1, wherein the immunofeature surface comprises one or more moieties that are positively charged, negatively charged, or neutral when the one or more moieties are in a buffered, aqueous solution at a pH in the range 7.2-7.4. 10. The composition of claim 1, wherein the surface of the synthetic nanocarriers further comprises a targeting moiety recognizing a target associated with a particular organ, tissue, cell, or subcellular locale. 11. The composition of claim 1, wherein the synthetic nanocarriers further comprise one or more of an immunostimulatory agent, an immunomodulatory agent, a B cell antigen, and a T cell antigen. 12. The composition of claim 11, wherein the immunostimulatory agent, B cell antigen, or T cell antigen is on: (i) the immunofeature surface; (ii) a second surface of the nanocarrier; or (iii) encapsulated within a core region of the nanocarrier. 13. The composition of claim 1, wherein the diameter of the nanocarriers is greater than 100 nm. 14. The composition of claim 1, wherein the pharmaceutically acceptable excipient is selected from solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, and lubricants. 15. The composition of claim 1, wherein the composition is effective at targeting a subcapsular sinus macrophage. 16. The composition of claim 1, wherein the composition is effective at targeting a dendritic cell. 17. The composition of claim 1, wherein the composition does not substantially activate complement. 18. A method comprising administering a first dose of the composition of claim 1 to a subject. 19. The method of claim 18, further comprising administering a second dose of the composition to the subject after an interval ranging from 1 day to 1 year. 20. The method of claim 19, wherein the interval ranges from 1 day to 1 month. 21. The method of claim 19, wherein the interval ranges from 1 day to 1 week. 22. A method for increasing the uptake of an antigen by a subcapsular sinus macrophage, comprising administering to a subject in need thereof a composition comprising: (1) a synthetic nanocarrier formed of a material selected from the group consisting of lipid-based nanoparticles, polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, peptide or protein-based particles comprising: (a) at least one surface comprising an immunofeature surface comprising a plurality of moieties that provide high avidity and low affinity binding to antigen presenting cell surfaces as compared to antibody binding; and(b) an antigen, wherein the antigen is on: (i) the immunofeature surface; (ii) a second surface of the nanocarrier; or (iii) encapsulated within a core region of the nanocarrier; and(2) a pharmaceutically acceptable excipient. 23. The method of claim 22, wherein the antigen is conjugated to the nanocarrier in a density equal to or greater than the density required to obtain at least 10% of the maximal immobilization observed for a monoclonal antibody (MAb) in an antigen presenting cell binding assay. 24. The method of claim 22, wherein the subcapsular macrophage is a CD169+macrophage. 25. The method of claim 22, wherein the nanocarrier further comprises an immunostimulatory agent on: (i) the immunofeature surface; (ii) a second surface of the nanocarrier; or (iii) encapsulated within the core region of the nanocarrier. 26. The composition of claim 1, where in the synthetic nanocarriers do not substantially activate the complement system.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (160)
Gerster John F. (Woodbury MN) Crooks Stephen L. (Mahtomedi MN) Lindstrom Kyle J. (Houlton WI), 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines.
Schmitz,Juergen; Dzionek,Andrzej; Buck,David William, Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby.
Arimilli Murty N. ; Cundy Kenneth C. ; Dougherty Joseph P. ; Kim Choung U. ; Oliyai Reza ; Stella Valentino J., Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Mikos Antonios G. (Houston TX) Sarakinos Georgios (Boston MA) Vacanti Joseph P. (Winchester MA) Langer Robert S. (Newton MA) Cima Linda G. (Lexington MA), Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures.
Barrera Denise (Oakdale MN) Langer Robert S. (Newton MA) Lansbury ; Jr. Peter T. (Brookline MA) Vacanti Joseph P. (Winchester MA), Biodegradable polymers for cell transplantation.
Vacanti Joseph P. ; Vacanti Charles A. ; Langer Robert S., Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous struct.
D\Amore Patricia (Brookline MA) Leong Kam W. (Cambridge MA) Langer Robert S. (Somerville MA), Bioerodible articles useful as implants and prostheses having predictable degradation rates.
Skwierczynski Raymond D. ; Phares Kenneth R. ; Miller Richard L. ; Li Zheng Jane ; Jozwiakowski Michael J. ; Busch Terri F., Formulations and methods for treatment of mucosal associated conditions with an immune response modifier.
Dalton,James T.; Miller,Duane D.; Steiner,Mitchell S.; Veverka,Karen A., Halogenated selective androgen receptor modulators and methods of use thereof.
Swain Philip A. ; Schad Victoria C. ; Greenstein Julia L. ; Exley Mark A. ; Fox Barbara S. ; Powers Stephen P. ; Gefter Malcolm L., Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same.
Kedl,Ross M.; Griesgraber,George W.; Zarraga,Isidro Angelo E.; Wightman,Paul D., Immunostimulatory compositions and methods of stimulating an immune response.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Bengs, Holger; Grande, Jürgen; Schuth, Silke; Böhm, Gitte; Schneller, Arnold; Brunner, Anette, Method for preparing smooth-surface spherical microparticles completely or partially made of at least one water-insoluble linear polysaccharide and microparticles produced according to this method.
Deming, Timothy J.; Yu, Miaoer; Curtin, Scott A.; Hwang, Jungyeon; Wyrsta, Michael D.; Nowak, Andrew; Seidel, Scott W., Methods and compositions for controlled polypeptide synthesis.
Jacobson Stephen C. ; Ramsey J. Michael, Microfabricated device and method for multiplexed electrokinetic focusing of fluid streams and a transport cytometry method using same.
Horoszewicz Julius S. (Williamsville NY), Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
Domb Abraham J. (Efrat ILX) Gref Ruxandra (Nancy FRX) Minamitake Yoshiharu (Ota JPX) Peracchia Maria T. (Parma ITX) Langer Robert S. (Newton MA), Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Domb Abraham J.,ILX ; Gref Ruxandra,FRX ; Minamitake Yoshiharu,JPX ; Peracchia Maria Teresa,ITX ; Langer Robert S., Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Mirkin, Chad A.; Letsinger, Robert L.; Mucic, Robert C.; Storhoff, James J.; Elghanian, Robert; Taton, Thomas A.; Garimella, Viswanadham; Li, Zhi, Nanoparticles having oligonucleotides attached thereto and uses therefor.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
Bischofberger Norbert W. ; Jones Robert J. ; Arimilli Murty N. ; Lin Kuei-Ying ; Louie Michael S. ; McGee Lawrence R. ; Prisbe Ernest J. ; Lee William A. ; Cundy Kenneth C., Nucleotide analogs.
Santus Giancarlo (Milan ITX) Bottoni Giuseppe (Bergamo ITX) Sala Giovanni (Verona ITX), Pharmaceutical controlled-release composition with bioadhesive properties.
Fessi Curt (Paris FRX) Devissaguet Jean-Philippe (Neuilly S/Seine FRX) Puisieux Francis (Maisons Alfort MO FRX) Thies Curt (St. Louis MO), Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles.
Cech Thomas R. (Boulder CO) Zaug Arthur J. (Louisville CO) Been Michael D. (Boulder CO), RNA ribozyme polymerases, dephosphorylases, restriction endoribo-nucleases and methods.
Hirosue Sachiko ; Mueller Bernhard G.,CHX ; Langer Robert S. ; Mulligan Richard C., Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids.
Larry Gold ; Michael Willis ; Tad Koch ; Steven Ringquist ; Kirk Jensen ; Brent Atkinson, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Gold Larry ; Willis Michael ; Koch Tad ; Ringquist Steven ; Jensen Kirk ; Atkinson Brent, Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.